Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits

Sang Won Min, Xu Chen, Tara E. Tracy, Yaqiao Li, Yungui Zhou, Chao Wang, Kotaro Shirakawa, S. Sakura Minami, Erwin Defensor, Sue Ann Mok, Peter Dongmin Sohn, Birgit Schilling, Xin Cong, Lisa Ellerby, Bradford W. Gibson, Jeffrey Johnson, Nevan Krogan, Mehrdad Shamloo, Jason Gestwicki, Eliezer MasliahEric Verdin, Li Gan

Research output: Contribution to journalArticlepeer-review

355 Scopus citations


Tauopathies, including frontotemporal dementia (FTD) and Alzheimer's disease (AD), are neurodegenerative diseases in which tau fibrils accumulate. Recent evidence supports soluble tau species as the major toxic species. How soluble tau accumulates and causes neurodegeneration remains unclear. Here we identify tau acetylation at Lys174 (K174) as an early change in AD brains and a critical determinant in tau homeostasis and toxicity in mice. The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy. The tau-lowering and protective effects of salsalate were diminished in neurons expressing K174Q tau. Targeting tau acetylation could be a new therapeutic strategy against human tauopathies.

Original languageEnglish
Pages (from-to)1154-1162
Number of pages9
JournalNature Medicine
Issue number10
StatePublished - 1 Oct 2015
Externally publishedYes


Dive into the research topics of 'Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits'. Together they form a unique fingerprint.

Cite this